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Understanding the natural history of thoracic aortic aneurysms (TAAs) is essential to patient care and surgical decision
making. In this evidence summary we discuss some of the most clinically relevant features of the disease. The true incidence of
TAAs is likely to be higher than currently reported because of the inherently silent nature of TAAs. However, TAAs can
become rapidly lethal once dissection or rupture occurs, highlighting the need for more robust screening. The impressive
discovery of familial patterns andnovel genetic loci forTAAs challenges the idea thatmostTAAs are simply sporadic. Although
the aorta grows in an indolent manner, its rate of growth and its current diameter both have important clinical implications.
Biomechanical studies have supported clinical findings of 6.0 cm as a dangerous threshold. Surgical extirpation of TAAs is
currently themainstay of effective treatment. Although endovascular TAA repair is becoming increasingly common, long-term
safety remains unproven. We still need more data to support the concept that any medical therapy is effective. (J Vasc Surg
2012;56:565-71.)
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pThe Centers for Disease Control and Prevention re-
ports that aortic aneurysms (thoracic and abdominal) are
the 15th leading cause of death in individuals aged 55
years and the 19th leading cause of death overall.1 Although
the prevalence of thoracic aortic aneurysms (TAAs) is likely
lower than the reported prevalence of abdominal aortic
aneurysms (AAAs), TAAs represent an important compo-
nent of vascular disease due to their particularly lethal
nature.2 We highlight in this evidence summary the follow-
ing specific characteristics of the natural history of TAAs.
EVIDENCE SUMMARY
TAA is likely to be much more common than we
recognize. The epidemiology of TAAs is challenging to
study because it is a clinically silent disease. Approximately
60% of TAAs occur in the root or ascending aorta, 10% in
the arch, 40% in the descending aorta, and 10% in the
thoracoabdominal aorta; however, an aneurysm may in-
volve multiple aortic segments.3 TAAs are asymptomatic in
95% of cases, meaning most TAAs remain undetected
unless incidentally discovered.2 In addition, many fatal
TAA ruptures or dissections are misdiagnosed as myocar-
dial infarction, thereby underestimating the true prevalence
of TAAs. The prevalence of asymptomatic TAAs has been
measured at between 0.16% and 0.34%4,5; however, these
studies defined TAA as aortic diameters 5 cm, thereby
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ized between 4 and 5 cm. The annual incidence of TAAs
as been assessed at approximately six to 10 cases/100,000
atient-years.6,7 Interestingly, the incidence of TAAs ap-
ears to be increasing, although it is not understood to
hat degree this observation is explained by an aging
opulation or more frequent imaging.2 On the basis of data
rom communities where the population is stable and post-
ortem examinations are done routinely, there appears to
e a bona fide increase in the true incidence of TAAs during
he past several decades.7,8
TAA appears to have a larger familial component than
reviously thought. Recent clinical series looking at the
endelian patterns in families of TAA patients have disclosed
efinite familial patterns.9 In fact, 21% of patients with TAAs
ave at least one family member with a known aneurysm of
ome sort; many more family members likely harbor un-
nown, undiagnosed aneurysms. Of these familial forms, 77%
re inherited in an autosomal-dominant manner with variable
xpressivity and penetrance (Fig 1).9,10
TAAs can also occur as part of complex genetic syn-
romes, including Marfan syndrome (most common),
hlers-Danlos syndrome, Loeys-Dietz syndrome, and
urner syndrome. However, these syndromes are just the
ip of the iceberg. Increasing numbers of genetic loci linked
o nonsyndromic TAAs are being identified.11 These novel
oci, and the inherent incompleteness of pedigrees, suggest
hat the true proportion of familial TAAs is 21%. There-
ore, physicians should be cognizant of screening family
embers of TAA patients. Of note, patients with familial
AAs generally present at an earlier age (56.8 years) than
atients with sporadic TAAs (64.3 years).10
Mutations causing TAAs can also underlie the forma-
ion of other types of aneurysm. For example, we have
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August 2012566 Kuzmik et alshown that 9% of TAA patients harbor concurrent intra-
cranial aneurysms, a prevalence that is significantly higher
than that in the general population.12
The aorta grows in an indolent manner. The aver-
age ascending aneurysmal aorta expands by 0.10 cm annu-
ally, whereas descending TAAs grow by 0.29 cm annu-
ally.13 Aneurysms with larger diameters tend to grow more
rapidly.13 It is important to appreciate that such measure-
ments fall within the margin of error for most computed
tomography (CT) scanners, and therefore, physicians
should be cautious about relying too heavily on these
measurements.14 In addition, the innate geometry of the
aorta, particularly as it dilates and becomes more tortuous,
poses inherent challenges in obtaining accurate measure-
ments from radiographic studies. The lack of standardiza-
tion regarding axis of measurement and inclusion of the
vessel wall further complicates the issue. When determining
the rate of TAA growth, comparison must be made not
with the most recent CT scan but with the earliest CT scan
Fig 1. Selected pedigrees of thoracic aortic aneurysm (
and levels of penetrance. Recent discoveries of novel loci u
proportion of TAAs that are genetic. Reproduced with pavailable so that small changes accruing over time can be Oully appreciated.15 Reports of rapid growth usually repre-
ent measurement error due to comparison of nonequiva-
ent aortic segments or tangential measurement across an
blique segment of aorta.14
Patients with familial TAAs have faster growth rates of
.21 cm/y (combined ascending and descending TAA)
ompared with patients with sporadic TAAs (0.16 cm/y)
nd thus present earlier.9 Syndromic TAA growth rates vary
s well. Marfan aortas grow at 0.1 cm/y, whereas TAAs of
he especially malignant Loeys-Dietz syndrome can grow
aster than 1.0 cm/y, resulting in mean age of death at 26
ears.9,16
TAA is silent and lethal. Before an acute event, 95%
f TAAs are asymptomatic.2 A diastolic murmur secondary
o aortic regurgitation may be audible with advanced dis-
ase, but only if the aneurysm involves the ascending aorta.
s a result, most aneurysms are detected incidentally
hrough imaging for an unrelated problem (eg, a CT scan
or a lung nodule, or echocardiography for a murmur).
) patients, demonstrating multiple inheritance patterns
ying familial TAAs supplement our understanding of the
ssion from Albornoz et al.9TAA
nderlnce aneurysms become symptomatic or painful, however,
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Volume 56, Number 2 Kuzmik et al 567surgical intervention is usually indicated regardless of aneu-
rysm size.17
Given that the 5-year survival of untreated TAA6 cm
falls to 54%,18 we cannot overemphasize the clinical need
for a robust screening test. Echocardiography is not sensi-
tive for aneurysms beyond the proximal ascending aorta,
and CT is too costly and harmful to serve as a generalized
screening test. We are currently researching gene expres-
sion profiles and other biomarkers as potential screening
modalities.19,20 Screening is especially important for high-
risk patients who have concurrent intracranial aneurysms or
AAAs, a family history of sudden death, persistent atypical
chest pain, or for relatives of patients with known aneu-
rysm.
We can predict the risk of rupture or dissection
based on aortic size. Data from our institution has shown
that the risk of natural complications (rupture, dissection)
from TAAs rises with increasing aortic diameter. The an-
nual risk of rupture or dissection is2% for TAAs between
4.0 and 4.9 cm, while reaching nearly 7% for TAAs 6.0
cm.18 We have also found that there is a drastic increase in
the risk of rupture or dissection beyond a diameter of 6.0
cm for an ascending TAA and 7.0 cm for a descending TAA
(Fig 2).13 Accordingly, preemptive surgical intervention is
necessary before the aorta reaches these dangerous thresh-
olds.17 However, other factors, such as the presence of
acute symptoms, a concomitant bicuspid aortic valve, a
connective tissue disease such as Marfan Syndrome, or a
rapidly enlarging aortic diameter, often warrant earlier in-
tervention at smaller aortic sizes.21
Once dissection or rupture occurs, short-term and
long-term outcomes diminish rapidly. The excruciating
chest pain or sudden death caused by acute aortic events is
frequently the first and only signs of a TAA. However,
physicians must also respect dissection as a great masquer-
ader that presents with variable or even absent symptoms.22
Aortic dissection and rupture occur with approximately the
same incidence of 3.5/100,000 patient-years.23 The prog-
Fig 2. Effects of aortic aneurysm size on risk of comp
Reproduced with permission from Coady et al.13nosis for acute aortic dissection is poor. Data from the anternational Registry of Acute Aortic Dissection (IRAD)
ndicate that overall in-hospital mortality for acute thoracic
ortic dissection is 27.4%.24 In-hospital mortality for acute
ype A dissection is 35% (26% in patients undergoing
urgical repair and 58% in patients managed nonoperatively
ue to age or comorbidities).24 Acute type B dissections
ave a more favorable in-hospital mortality of 12%, with
ortality rates of 29%, 11%, and 10% for patients receiving
urgical, endovascular, and medical management, respec-
ively.25
In cases of chronic dissection, or even after successful
artial aortic replacement, the residual aorta will grow at an
ccelerated rate.26 As a consequence, these patients have a
everely compromised long-term outlook: nearly 40% will
uffer fatal rupture or require additional intervention.27
The prognosis for TAA rupture is worse than dissec-
ion. One study found that only 41% of patients with TAA
upture reach a hospital alive.28 For those patients who do
urvive to operation, data from a nationwide study indicate
hat the perioperative mortality of surgical repair of the
escending aorta is 28.6%, whereas the mortality of endo-
ascular repair is 23.4% (risk-adjusted mortality and com-
lication rates were not significantly different between the
wo treatments).29 Because of the potential misdiagnosis of
upture-related death as cardiac arrest, aortic ruptures likely
ave an even higher mortality rate than we suspect. These
ismal statistics underscore the need for early recognition
f TAAs in the general population.
Mechanical properties of the aorta correlate well
ith its clinical behavior. We have shown that the clinical
anger threshold for rupture mirrors the innate physical
imits of the aortic wall. As the aorta approaches 6.0 cm, its
istensibility rapidly falls.30 At this size, the aorta loses its
atural elasticity and effectively becomes a rigid tube. Pres-
ure on the vessel wall therefore cannot be dissipated and
esults directly in increased wall stress. Indeed, once the
orta reaches 6.0 cm, the measurable wall stress markedly
ises (Fig 3).30 At a blood pressure of 200 mm Hg, easily
ions for the (A) ascending and (B) descending aorta.licatchieved through strenuous exercise or emotional distress,
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tensile strength of aortic tissue.30 It is therefore not surpris-
ing that 6.0 cm represents the danger threshold for rupture
and dissection.
Surgical extirpation of TAAs restores life
expectancy. Although TAA is often a lethal disease if left
Fig 3. Relationship between wall stress and aortic size
blood pressures of 100 mm Hg (dark bars) and 200 mm
strength of aortic tissue. Reproduced with permission fro
Fig 4. Kaplan-Meier survival after elective surgery, med
permission from Davies et al.18untreated, early surgical intervention provides good long- serm outcomes. Elective surgical treatment of TAAs not
nly improves survival over medical management alone but
lso achieves a survival curve approaching that of the
ealthy, age-matched population (Fig 4).18 The 5-year
urvival after elective extirpation of a TAA is 85%. In
ontrast, emergency surgical intervention does not yield
cending aortic aneurysms. The bars show wall stress at
light bars). The dashed lines represent maximum tensile
oullias et al.30
anagement, and emergency surgery. Reproduced within as
Hg (ical much favorable outcomes, with a5-year survival of 37%.18
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Volume 56, Number 2 Kuzmik et al 569The benefits of surgical management are reinforced by the
safety of TAA repair procedures relative to the lifelong risks
of rupture or dissection.
At our institution, the surgical mortality rates are 3.0%
for elective ascending/arch repair and 2.9% for descending
TAA repair.31 The rates of serious perioperative complica-
tions are similarly low. Endovascular techniques are being
used for descending TAA repair, with encouraging results.
Perioperative mortality for various devices is between 5.8%
and 6.1%, with mortality and complication rates that are
often lower than those for surgical comparison groups.32,33
Successful endovascular or hybrid approaches to repair
ascending TAAs have also been reported.34 Nonetheless,
there are concerns regarding the long-term durability and
safety of endovascular TAA repair in contrast to surgical
repair.35
Overall, these outcomes strongly reinforce the need to
repair a TAA before it reaches the dangerous thresholds of
6.0 cm for the ascending aorta and 7.0 cm for the descend-
ing aorta, at which the risk of rupture increases sharply (Fig
2). We recommend repairing an ascending TAA once it
reaches 5.5 cm and a descending TAA at 6.5 cm, although
intervention is indicated at smaller diameters in patients
with symptomatic aneurysms, rapidly enlarging aneurysms,
or those with connective tissue disease.17 The presence of a
bicuspid aortic valve, which represents the most common
congenital heart condition, also warrants aortic repair at
smaller diameters (we recommend 5.0 cm) due to the
Fig 5. Convergence of several molecular mechanisms
many of these mechanisms in principle, although clinical
for general aneurysm management. ACEI, angiotensin
blocker; AT1, angiotensin 1; MMP, matrix metalloprot
NADPH, reduced nicotinamide adenine dinucleotide p
growth factor. Reproduced with permission from Danyiincreased risk of dissection.2 pEvidence for effectiveness of medical therapy for
AA is scant. -Blockers were initially proposed as med-
cal therapy for TAAs based on their ability to reduce blood
ressure, cardiac inotropy, and shear stress on the aorta (Fig
).36 However, clinical benefit of -blockers has been
emonstrated in only one study of Marfan patients.37 No
tudies to date have confirmed this finding on non-Marfan
AA patients. Some studies, in fact, suggest that -blockers
o not protect against TAA growth.38
Statins were studied as treatment for AAAs based on
heir lipid-lowering and antioxidative effects. Yet, the larg-
st, most recent study to date found no benefit of statins on
AA growth.39 A recent study from our institution, how-
ver, did find a substantial benefit from statins in preventing
upture, dissection, death, and need for surgical interven-
ion in patients with TAAs (Fig 6).40 This exciting finding
eeds further corroboration.
Studies on angiotensin-converting enzyme inhibitors
nd angiotensin receptor blockers have reported conflicting
esults.41 Losartan may have a protective effect by antago-
izing the activity of transforming growth factor-.42 A
ulticenter randomized controlled trial (COzaar inMarfan
atients Reduces aortic Enlargement [COMPARE]) is un-
erway to confirm these findings.
ONCLUSIONS
At present, we believe surgery remains the mainstay of
AA treatment. Although endovascular techniques hold
eurysm formation. Candidate medical therapies target
fit has yet to be demonstrated for all of these candidates
verting enzyme inhibitor; ARB, angiotensin-receptor
; NADH, reduced nicotinamide adenine dinucleotide;
hate; ROS, reactive oxygen species; TGF, transforming
41of an
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en; recent data from a large nationwide study indicate that
survival for endovascular repair after 1 and 5 years is worse
than open surgical repair.33,35 We also recommend smok-
ing cessation and avoidance of stressful activity for TAA
patients.43 Understanding the natural history of TAA is
contributing to rational, evidence-based surgical decision
making and helping us to tame this virulent disease.
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